NEWS COMMENTARY

Pear Therapeutics acquires DTx assets used to treat depression, in sign of a warming market for tech-aided therapy

Published:
December 22, 2021
Last Updated:
December 27, 2021
Services:
CPG More...
Priorities:
Consumer Health and Wellness More...
Activities:
Acquisition
Very important

The acquisition of Waypoint Health Innovations further underscores Pear’s focus on its psychiatry portfolio. Before this acquisition, Pear already had a product in its development pipeline (Pear-015). Waypoint's assets deliver cognitive behavioral therapy that dynamically personalizes each individual’s experience. The treatment of depression is a large market, with 4.7% of American adults, around 12 million people, experiencing regular symptoms of depression. This market is expected to grow further with the challenges brought on by the pandemic era. Clients should move quickly to identify suitable investment or partnership opportunities at the intersection of digital therapeutics (DTx) and mental health.

For the original news article, click here .


Further Reading

Abbott plans to develop a line of consumer wearables, pushing deeper into consumer health and nutrition

News Commentary | January 14, 2022

Abbott announced its plans to develop a new category of consumer wearables called Lingo at CES 2022. Lingo aims to measure biomarkers such as glucose, ketones, and lactates, which provide insights into physiological conditions like ketosis and lactate buildup after exercise. This announcement ... To read more, click here.

Royal Philips begins clinical trials for first at-home ECG solution

News Commentary | February 07, 2022

Philips' device will be the industry's first attempt at an at‑home, 12‑lead ECG (electrocardiogram). It will include access to Philips' cardiac monitoring portfolio, which pairs cloud‑based data collection with data readings it claims are comparable to clinical ECGs. While the solution is still in ... Not part of subscription

News Trends: Digital health Q1 2022 update

Research Brief | April 21, 2022

The first quarter of 2022 saw a number of interesting developments across the many different verticals of digital health. Partnerships, acquisitions, funding, and product developments over a variety of markets have grown since the end of 2021. Partnerships across the world of digital therapeutics... Not part of subscription